What is The Medicines Co Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. The Medicines Co's interest expense for the
three
months ended in Sep. 2019 was $ -16.21 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2019 was $-60.94 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. The Medicines Co's Operating Income for the
three
months ended in Sep. 2019 was $ -61.37 Mil. The Medicines Co's Interest Expense for the
three
months ended in Sep. 2019 was $ -16.21 Mil.
The Medicines Co did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The Medicines Co Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Medicines Co (NAS:MDCO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The Medicines Co's Interest Expense for the
three
months ended in Sep. 2019 was $-16.21 Mil. Its
Operating Income
for the
three
months ended in Sep. 2019 was $-61.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2019 was $464.99 Mil.
The Medicines Co's Interest Coverage for the quarter that ended in Sep. 2019 is calculated as
| The Medicines Co did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
The Medicines Co (The Medicines Co) Business Description
Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, NJ, USA, 07054
The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.
Executives
| Alexander J Denner |
director |
C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
| Peter Wijngaard |
officer: Chief Development Officer |
8 SYLVAN WAY, PARSIPPANY NJ 07054 |
| Paris Panayiotopoulos |
director |
ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Geno J Germano |
director |
5 GIRALDA FARMS, MADISON NJ 07940 |
| Sarah J. Schlesinger |
director |
C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Christopher T Cox |
officer: EVP & Chief Corp. Dev. Officer |
CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281 |
| Fredric N Eshelman |
director, officer: Executive Chairman |
PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401 |
| Armin M Kessler |
director |
|
| Robert J Hugin |
director |
C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054 |
| Hiroaki Shigeta |
director |
THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054 |
| Stuart A Kingsley |
officer: President and COO |
152 CHESTNUT STREET, WEST NEWTON MA 02465 |
| Robert G. Savage |
director |
C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591 |
| Glenn Sblendorio |
director, officer: President & CFO |
3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036 |
| James E Flynn |
10 percent owner, other: Possible Members of 10% Group |
780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
| Deerfield Management Company, L.p. (series C) |
10 percent owner, other: Possible Members of 10% Group |
345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
The Medicines Co (The Medicines Co) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MDCO has been successfully added to your 